A Phase 2 clinical trial of PX-578.
Latest Information Update: 20 Mar 2026
At a glance
- Drugs PX 578 (Primary)
- Indications Mitochondrial disorders
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
Most Recent Events
- 20 Mar 2026 New trial record
- 12 Mar 2026 According to the Pretzel Therapeutics media release, company will initiate a Phase 2 study in second half of 2026.